This dilutive offering at a 25% discount to market price signals acute capital needs from a company with a going-concern warning and only ~3 months of cash at current burn rate. The warrants add further overhang. Monitor for additional financing needs within 6-12 months and any clinical data catalysts that could alter the cash runway trajectory.
Price Chart
Executive Summary
Atossa Therapeutics is conducting a registered direct offering of 1,363,637 shares of common stock at $3.30 per share, bundled with Series A and Series B warrants to purchase up to 2,727,274 additional shares at $4.40 per share. The company expects net proceeds of approximately $4.1 million for clinical development and working capital, but explicitly states these funds are insufficient to complete development of any product candidate. The filing also discloses a going-concern warning, with existing resources likely insufficient to fund operations for the next 12 months.
Key Facts
- Offering 1,363,637 shares at $3.30 per share, representing ~13.7% dilution of outstanding shares
- Warrants to purchase up to 2,727,274 additional shares at $4.40 per share (exercisable starting 6 months from issuance)
- Net proceeds estimated at ~$4.1 million after fees and expenses
- Company states existing resources likely insufficient to fund operations for next 12 months
- Net loss of $9.6 million for Q1 2026, accumulated deficit of $256.2 million
- Cash and cash equivalents of $31.7 million as of March 31, 2026
- Offering priced at $3.30 vs last sale price of $4.40 on June 10, 2026 (25% discount)
- Placement agent fees of 7.0% of gross proceeds ($315,000) plus warrants
Financial Impact
Dilution of ~13.7% from share issuance, plus potential dilution of up to 27.3% from warrants if exercised. Net proceeds of ~$4.1M are insufficient to fund operations beyond near term given $9.6M quarterly cash burn.
Risk Factors
- Going-concern risk: company states existing resources insufficient for 12 months of operations
- Significant dilution: 13.7% from shares plus up to 27.3% from warrants
- Warrant overhang: 2.7M shares exercisable at $4.40 (at-the-money) could pressure stock
- No revenue and $9.6M quarterly net loss
- Nasdaq compliance risk (recently regained minimum bid price after reverse split)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-268597 |
| Document: 0001193125-26-268597-index-headers.html | 0001193125-26-268597 |
| Document: 0001193125-26-268597-index.html | 0001193125-26-268597 |
| Document: 0001193125-26-268597.txt | 0001193125-26-268597 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $2.44 | awaiting T+60 | — | $2.38 (−2.46%) |
Sep 29, 2026 28d ago | 8-K | $1.99 | awaiting T+60 | — | $2.38 (+19.60%) |
Sep 18, 2026 5w ago | 8-K | $2.25 | awaiting T+60 | — | $2.38 (+5.78%) |
Aug 7, 2026 11w ago | 8-K | $2.36 | awaiting T+60 | — | $2.38 (+0.85%) |
Aug 7, 2026 11w ago | Press Release | $2.36 | awaiting T+60 | — | $2.38 (+0.85%) |
Jun 12, 2026 19w ago | 424B5 | $2.46 $2.52 | ▼ −2.24% | ▲ +1.03% | $2.38 (+3.25%) |
Apr 16, 2026 27w ago | 8-K | $5.77 $2.40 | ▼ −58.41% | ▼ −65.45% | $2.38 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers